Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02616094 · ClinicalTrials.gov registry record · NA

Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
224
Enrollment target

NCT02616094: Completed NA study, sponsored by Yale University.

NCT02616094 is a NA study that has completed, run by Yale University. The registered enrollment target is 224 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02616094, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
224 participants
Enrollment target

Study Summary

Extending previous findings, and applying a novel multi-method translational approach, this project hypothesizes that there are alcohol-related neuroendocrine and neural changes observable in acute and protracted abstinence, and which can accurately classify future relapse and treatment outcome in separate alcohol dependent (AD) patient samples, thereby validating them as biomarkers of relapse, with potential clinical utility as prognostic markers in identifying and treating those most susceptible to relapse.

Primary Outcome

The Time-Line Follow-Back Interview will be used to assess alcohol use in the previous ninety days, during the study and during follow-up until relapse occurs or 200 days is up.

Interventions

  • DEVICE Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
  • DEVICE Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2015-11
Est. Completion 2022-06-30
Phase NA
Yale University

1,492 total trials

What the finished NCT02616094 record still lists

NCT02616094 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 2 interventions - of which Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1 is the first listed.

NCT02616094 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02616094 about?

NCT02616094 is a clinical study titled "Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse". Extending previous findings, and applying a novel multi-method translational approach, this project hypothesizes that there are alcohol-related neuroendocrine and neural changes observable in acute and protracted abstinence, and which can accurately classify future relapse and treatment outcome in s...

What is the current status of trial NCT02616094?

This trial is currently completed. It is a NA study. The enrollment target is 224 participants. The study started on 2015-11. Estimated completion is 2022-06-30.

What interventions are being tested in trial NCT02616094?

The interventions under investigation include: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1 (DEVICE), Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2 (DEVICE).

Who is sponsoring clinical trial NCT02616094?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02616094's enrollment target sits among peer trials

224 478th of 2000 higher than 1,520 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

  • NCT04140344 · 224 participants · NA

    The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

  • NCT04915183 · 224 participants · Phase 2

    Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

  • NCT05519878 · 224 participants · NA

    Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02616094, the US trial registry maintained by the National Library of Medicine. NCT02616094 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.